Effect of ubenimex (Bestatin®) on syngeneic bone marrow transplantation in leukemic mice

International Journal of Immunotherapy

Volumn 15, Issue 3-4, 1999, Pages 99-106

  Kikuchi, K ^a   Sekine, K ^a   Morohashi, H ^a   Ishizuka, M ^b   Hirai, H ^c   Abe, F ^a  

^a NIPPON KAYAKU CO LTD   (Japan)

^b Microbial Chemistry Research Foundation   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BESTATIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; ISOGRAFT; LEUKEMIA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; SURVIVAL TIME; T LYMPHOCYTE; X IRRADIATION;

EID: 0033499911     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Abe F., Fujii A., Yoshimura K., Yugeta E., Ishizuka M., Takeuchi T. Immunomodulatory and therapeutic characteristic of bestatin (ubenimex). Int. J. Immunotherapy, 6, 203, 1990.
2. Ohta K., Kurita S., Yamada K., Masaoka T., Uzuka T., Ogawa T. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol. Immunotherapy, 23, 5, 1986.
3. Urabe A., Mutoh Y., Mizoguchi H., Takaku F. Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann. Hematol., 67, 63, 1993.
4. Talmadge J.E., Ino K., Bierman P.J. Bestatin for anticancer treatments. In: Kimball E.S. (Ed.). "Immunopharmaceuticals". CRC Press Inc., Boca Raton, 1996, pp. 135-166.
5. Talmadge J.E., Lenz B.F., Pennington R., et al. Immunomodulatory and therapeutic properties of Bestatin in mice. Cancer Res., 46, 4505, 1986.
6. Ino K., Bierman P.J., Varney M.L., et al. Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation. Cancer Immunol. Immunother., 43, 206, 1996.
7. Majima H., Suzuki M. Phase I clinical study of bestatin: Effect on immunological parameters. Jpn. J. Cancer Chemotherapy, 8, 278, 1981.
8. Sasaki S., Fukushima J., Hamajima K., et al. Adjuvant effect of ubenimex on a DNA vaccine for HIV-1. Clin. Exp. Immunol., 111, 30, 1998.
9. Talmadge J.E., Pelus L.M., Black P.L., Abe F. Hematopoietic and therapeutic properties of Bestatin in normal and myelosuppressed mice. Biomed. Pharmacother., 45, 61, 1991.
10. Aoki I., Higashi K., Nishijima K., Homori M., Chikazawa H., Ishikawa K. Effects of ubenimex on erythroid progenitors (CFU-E and BFU-E) in human bone marrow. Exp. Hematol., 19, 893, 1991.
11. Shibuya K., Chiba S., Hino M., et al. Enhancing effect of ubenimex (bestatin) on proliferation and differentiation of hematopoietic progenitor cells, and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation. Biomed. Pharmacother., 45, 71, 1991.
12. Jones R.J., Ambinder R.F., Plantadosi S., Santos G.W. Evidence of graft versus-host-lymphoma effect associated with allogeneic bone marrow. Blood, 77, 649, 1991.
13. Talmadge J.E., Tribble H., Pennington R., et al. Protective, restorative, and therapeutic properties of recombinant colony-stimulating. Blood, 73, 2093, 1989.
14. Abe F., Shibuya K., Uchida M., et al. Effect of bestatin on syngeneic tumors in mice. Gann., 75, 89, 1984.
15. Charak B.S., Brynes R.K., Chogyoji M., Kortes V., Tefft M., Mazumder A. Graft versus leukemia effect after transplantation with interleukin-2-activated bone marrow. Transplantation, 56, 31, 1993.
16. Hadden J.W., Renoux G., Chrigos M. The characterization of immunotherapeutic agents. Immunopharmac. Rev., 1, 1, 1990.
17. Shibuya K., Hayashi E., Abe F., et al. Enhancement of interleukin-1 and interleukin-2 releases by ubenimex. J. Antibiot., 40, 363 (1987).
18. Ohhara N., Okamura S., Niho Y., Otsuka T. Stimulatory effect of an aminopeptidase inhibitor on human bone marrow CFU-C mediated by the interaction of T-lymphocytes. Acta. Hematol. Jpn., 48, 1012 1985.
19. Blazsek I., Comisso M., Misset J.L. Modulation of bone marrow cell functions in vitro by bestatin (ubenimex). Biomed. Pharmacother., 45, 81, 1991.
20. Ishizuka M., Masuda T., Mizutani S., Takeuchi T., Umezawa H. (1986). Activation of antitumor effector cells in tumor-bearing mice by bestatin. In: Umezawa H. (Ed.). "Recent Results of Bestatin 1986 - A Biological Response Modifier". Jpn. Antibiot. Res. Assoc., Tokyo, 1986, p. 1.
21. Slavin S., Ackerstein A., Naparstek E., Or R., Weiss L. Hypothesis: The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplantation, 6, 155, 1990.